2015
Targeted Therapy in Solid Tumors: Lung Cancer
Waqar S, Morgensztern D, Herbst R. Targeted Therapy in Solid Tumors: Lung Cancer. 2015, 224-230. DOI: 10.1002/9781118468678.ch23.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerManagement of NSCLCMetastatic non-small cell lung cancerChoice of regimensUnprecedented response ratesProgression-free survivalEarly-stage diseaseIncurable metastatic diseaseCell lung cancerImproved cure ratesToxic treatment optionsMetastatic diseaseStage diseaseCure rateTreatment optionsTargeted therapyToxicity profileSecondary resistanceResponse rateSolid tumorsPatientsTumor progressionTherapyTumors
2014
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
Henick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion On Therapeutic Targets 2014, 18: 1407-1420. PMID: 25331677, DOI: 10.1517/14728222.2014.955794.Peer-Reviewed Original ResearchConceptsPD-1 pathwayEarly clinical trialsClinical trialsTumor typesDeath-1 pathway inhibitorsPD-1 pathway inhibitionImmune escape mechanismsOngoing clinical trialsEarly-stage cancerTreatment of cancerCure rateLikely respondersCancer immunotherapyPreclinical dataAntineoplastic effectsTherapeutic targetPathway inhibitionPathway inhibitorCancer typesBiological rationaleCancer treatmentMonoclonal antibodiesEscape mechanismsUpcoming trialsTrials